Stock Comparison

ABBV vs PBYI

AbbVie Inc vs Puma Biotechnology Inc

The Verdict

PBYI takes this one.

ABBV

AbbVie Inc

0.1

out of 10

Distressed

Winner

PBYI

Puma Biotechnology Inc

2.0

out of 10

Risk Trap

Head-to-Head

$381.1B

Market Cap

$382M

104.8

P/E Ratio

12.3

5.8%

Profit Margin

13.6%

95.6%

Return on Equity

27.8%

20.2

Debt-to-Equity

0.2

Moderate

Overall Risk

Aggressive

0.1

DVR Score

2.0

The Deep Dive

ABBV0.1/10

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Full ABBV Analysis

PBYI2.0/10

Puma Biotechnology remains a highly speculative investment with limited 10x growth potential within 3-5 years. While the company exhibits a strong balance sheet and explicitly positive TTM free cash flow ($41.73M), which provides financial stability, the core business faces significant headwinds. Previous intelligence indicated declining new prescriptions for NERLYNX and a projected revenue declin...

Full PBYI Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.